Teva Pharmaceutical Industries Limited (NYSE:TEVA) Holdings Raised by Captrust Financial Advisors

Captrust Financial Advisors increased its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 48.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 15,786 shares of the company’s stock after purchasing an additional 5,146 shares during the quarter. Captrust Financial Advisors’ holdings in Teva Pharmaceutical Industries were worth $284,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of TEVA. Envestnet Portfolio Solutions Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the second quarter worth approximately $188,000. Coronation Fund Managers Ltd. purchased a new position in Teva Pharmaceutical Industries during the 2nd quarter worth approximately $1,334,000. Blue Trust Inc. raised its stake in Teva Pharmaceutical Industries by 164.0% during the 2nd quarter. Blue Trust Inc. now owns 10,434 shares of the company’s stock valued at $170,000 after purchasing an additional 6,481 shares during the period. Raymond James & Associates lifted its holdings in shares of Teva Pharmaceutical Industries by 5.1% in the second quarter. Raymond James & Associates now owns 815,944 shares of the company’s stock valued at $13,259,000 after purchasing an additional 39,610 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its position in shares of Teva Pharmaceutical Industries by 40.3% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 289,279 shares of the company’s stock worth $4,701,000 after buying an additional 83,117 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TEVA. UBS Group raised their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $19.67.

Insiders Place Their Bets

In related news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 1.8 %

Teva Pharmaceutical Industries stock opened at $16.50 on Friday. The company has a market capitalization of $18.69 billion, a P/E ratio of -19.41, a P/E/G ratio of 1.04 and a beta of 0.79. Teva Pharmaceutical Industries Limited has a 1-year low of $9.90 and a 1-year high of $19.31. The firm’s fifty day simple moving average is $17.49 and its 200-day simple moving average is $17.39. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.